172. Hypophosphatasia Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 34 Drugs : 17 - (DrugBank : 4) / Drug target genes : 3 - Drug target pathways : 6

Drugs and their primary sponsors and trial info
ALXN1850   
   Alexion Pharmaceuticals
      2021   Phase 1   NCT04980248   United States;
Asfotas Alfa   
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain;
Asfotase Alfa (ALXN1215)   
   Translational Research Informatics Center, Kobe, Hyogo, Japan
      2014   Phase 2   NCT02456038   Japan;
Asfotase alfa   
   Alexion Pharma GmbH
      2011   Phase 2   EUCTR2010-019850-42-DE   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
   Alexion Pharma GmbH
      2013   Phase 2   EUCTR2010-019850-42-GB   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 2   EUCTR2009-009369-32-GB   United Arab Emirates;United Kingdom;United States;
   Alexion Pharma International Sàrl
      2013   Phase 2   EUCTR2010-019850-42-IT   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 2   EUCTR2010-019850-42-ES   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      -   Phase 2   EUCTR2010-019850-42-FR   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
   Alexion Pharmaceuticals
      2020   Phase 4   NCT04189315   -
      2019   -   NCT04195763   United States;
      2016   Phase 2   NCT02797821   Germany;United States;
      2016   -   NCT02496689   France;United States;
      2010   Phase 2/Phase 3   NCT01176266   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2010   Phase 2   NCT01163149   Canada;United States;
      2009   Phase 2   NCT01205152   United Arab Emirates;United Kingdom;United States;
      2009   Phase 2   NCT00952484   Canada;United States;
      2008   Phase 1/Phase 2   NCT00744042   Canada;United Arab Emirates;United Kingdom;United States;
   HPP study group
      2014   -   JPRN-UMIN000014816   Japan;
BPS804   
   Novartis Pharma Services AG
      2011   -   EUCTR2010-024013-31-DE   Germany;
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01406977   Germany;
Biochemical analysis of different bone markers.   
   Hvidovre University Hospital
      2019   -   NCT04181164   Denmark;
Cyclophosphamide   
   Shimane University School of Medicine
      2010   Phase 2,3   JPRN-UMIN000003828   Japan;
ENB-0040   
   Alexion Pharma International Sarl
      2009   Phase 2   NCT00894075   United States;
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain;
      2013   Phase 2   EUCTR2010-019850-42-IT   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 2   EUCTR2010-019850-42-ES   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      -   Phase 2   EUCTR2010-019850-42-FR   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
   Enobia Canada Limited Partnership
      2009   -   EUCTR2008-007406-11-GB   United Kingdom;
Fully human IgG2 lambda monoclonal antibody   
   Novartis Pharma Services AG
      2011   -   EUCTR2010-024013-31-DE   Germany;
Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein   
   Alexion Pharma GmbH
      2011   Phase 2   EUCTR2010-019850-42-DE   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
   Alexion Pharma GmbH
      2016   Phase 2   EUCTR2015-003131-35-DE   Germany;United States;
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain;
   Enobia Canada Limited Partnership
      2009   -   EUCTR2008-007406-11-GB   United Kingdom;
Human recombinant tissue non-specific alkaline phosphatase fusion protein   
   Alexion Pharma GmbH
      2013   Phase 2   EUCTR2010-019850-42-GB   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 2   EUCTR2009-009369-32-GB   United Arab Emirates;United Kingdom;United States;
      -   Phase 2   EUCTR2017-003153-42-Outside-EU/EEA   Canada;United States;
      -   Phase 2   EUCTR2017-001831-38-Outside-EU/EEA   Canada;United States;
   Alexion Pharma International Sàrl
      2013   Phase 2   EUCTR2010-019850-42-IT   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2013   Phase 2   EUCTR2010-019850-42-ES   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      -   Phase 2   EUCTR2010-019850-42-FR   Argentina;Australia;Canada;France;Germany;Italy;Japan;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      -   -   EUCTR2015-001128-52-Outside-EU/EEA   Canada;United States;
Methotrexate   
   Shimane University School of Medicine
      2010   Phase 2,3   JPRN-UMIN000003828   Japan;
Retrospective Case Only   
   Alexion Pharmaceuticals
      2014   -   NCT02235493   United States;
Strensiq   
   Alexion Pharma GmbH
      2011   Phase 2   EUCTR2010-019850-42-DE   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
   Alexion Pharma GmbH
      2016   Phase 2   EUCTR2015-003131-35-DE   Germany;United States;
      2013   Phase 2   EUCTR2010-019850-42-GB   Australia;Canada;France;Germany;Italy;Japan;Russian Federation;Saudi Arabia;Spain;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 2   EUCTR2009-009369-32-GB   United Arab Emirates;United Kingdom;United States;
      -   Phase 2   EUCTR2017-003153-42-Outside-EU/EEA   Canada;United States;
      -   Phase 2   EUCTR2017-001831-38-Outside-EU/EEA   Canada;United States;
   Alexion Pharma International Sàrl
      2016   Phase 4   EUCTR2015-000809-39-FR   Belgium;France;Netherlands;Russian Federation;Spain;